Drug Profile
Paracetamol/opioid analgesic controlled-release - Medtronic/Assertio Therapeutics
Alternative Names: Acetaminophen/opioid analgesic controlled-release - Covidien/DepomedLatest Information Update: 20 Aug 2018
Price :
$50
*
At a glance
- Originator Covidien; Depomed
- Developer Medtronic
- Class Acetanilides; Non-opioid analgesics; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 15 Aug 2018 Depomed is now called Assertio Therapeutics
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pain in USA (PO, Controlled release)
- 30 Nov 2011 Covidien initiates a Phase-I trial of a second controlled-release paracetamol/opioid analgesic product for Pain in USA